【Molecular composition】：

【CAS】：183321-74-6

【source】：Erlotinib

【Certification】：US FDA / Mexico COFEPRIS

【Spec】：Form A/Form B

【DMF】：Available

【use】：

Erlotinib is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.